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Abstract
Colorectal cancer is a leading cause of cancer-related death in the United States, despite recent advances in
treatment strategies. The immune system has been implicated in the pathogenesis of colorectal cancer, with
numerous studies identifying either antagonistic or pro-tumorigenic effects of infiltrating immune cells. Therapeutic
strategies harnessing the immune system to target cancers have evolved expediently over the last 5 years,
especially the use of checkpoint inhibitors. Recently, a subset of patients whose colorectal cancers harbor a
deficiency in mismatch repair proteins have demonstrated dramatic and durable response to checkpoint blockade.
Unfortunately, the vast majority of colorectal cancers are mismatch repair proficient and resistant to these inhibitors.
The tumor microenvironment has been implicated in the resistance to checkpoint block and ways to overcome
these resistance mechanisms would be a major advance for the treatment of colorectal cancer. Here we provide
commentary on a manuscript from Halama et al. examining CCL5/CCR5 as an immune biomarker and the potential
role of anti-CCR5 agents for the treatment of patients with colorectal cancer.
Background
Over the last 5 years, the use of immunotherapeutics
has gained significant enthusiasm for the treatment of
many cancers. In colorectal cancer (CRC), the immune
system plays an important role, as multiple studies have
demonstrated the prognostic importance of immune cell
infiltration [1–4]. The immunoscore—which categorizes
the location, type, and quantity of tumor-infiltrating
lymphocytes (TILs)—has been revealed as one of the
strongest prognostic markers in CRC. The immunoscore
quantifies the density of cytotoxic (CD8+) and memory
(CD45RO+) T cells (CD3/CD45RO, CD3+/CD8+ or
CD8+/CD45RO+) located in the center and invasive
margins of CRC cancers [1, 5]. Higher immunoscores,
indicating increased infiltration of CD8+ and CD45RO+
T lymphocytes into the invasive margin and central tumor,
are strong positive prognostic markers [1].
Agents targeting PD-1/PD-L1 or CTLA4 have demon-
strated robust benefit for multiple cancer types, but their
efficacy was limited in CRC until tested in the setting of
high microsatellite instability (MSI-H). Pembrolizumab,
an anti-PD-1 checkpoint inhibitor, resulted in an
exciting objective response rate and overall survival (OS)
in a subset of CRC patients with mismatch repair
deficiency (dMMR) [6]. In an updated analysis presented
at the American Society of Clinical Oncology annual
meeting, patients with dMMR CRC had a response rate
of 50% and a disease control rate of 89% compared to
no response observed in the mismatch repair proficient
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cancers [7]. Impressively, patients with dMMR treated
with pembrolizumab have durable responses with 61%
without progression after 24 months. These tumors are
characterized by deficiency in mismatch repair proteins
resulting in high mutational burdens and the potential
for increased neoantigen presentation. However, a high
mutational load alone does not determine responses to
checkpoint immunotherapy. In addition, since MSI-high
is seen in only ~4% of metastatic CRC, further investiga-
tions are required to better understand how immuno-
therapies can be used for MSS CRCs.
Interestingly, MSI status and quantification of the
number of TILs do not fully predict outcomes in patients
with CRC. A cohort of CRCs has been described that con-
tain a signature characterized by high lymphoid gene ex-
pression, and somewhat unexpectedly, was associated
with a worse prognosis [8]. These CRCS also have an in-
creased mesenchymal and myeloid infiltration. A mesen-
chymal signature was also recently reported in a cohort of
melanoma patients who were considered resistant to
checkpoint blockade [9]. This signature consists of genes
associated with the epithelial-to-mesenchymal transition,
immunosuppressive genes, and monocyte/macrophage
chemotactic genes.
While manipulation of specific subsets of immune
cells can lead to tumor response, as above, Halama and
colleagues have identified an immunologically distinct
microenvironment at the invasive margins of CRC liver
metastases in the setting of increased macrophage-
related cytokines and chemokines [10]. Increased levels
of CCL5, which is secreted by T cells, were identified at
the invasive margin. The production of CCL5 results in
tumor cell proliferation, invasion and increased produc-
tion of matrix metalloproteinases by tumor-associated
associated macrophages. These investigators then sought
to determine if maraviroc, a CCR5 inhibitor originally
developed for the treatment of HIV, would have anti-
neoplastic properties through inhibition of CCL5/CCR5
signaling using CRC tumor explants. Morphologic
changes consistent with tumor cell death were observed
in addition to mitigation of tumor-promoting cytokines.
Further investigation as part of a phase I clinic trial was
performed in a total of 14 patients with late-line
treatment-refractory metastatic CRC. Pre- and post-
treatment biopsies were obtained for pharmacodynamic
analyses and demonstrated that maraviroc as a single
agent reduced tumor proliferation, reduced certain
cytokines and caused morphologic changes consistent
with tumor cell death. This therapy was well-tolerated.
Clinically, however, as a single agent no responses were
observed and the median PFS was only 1.15 months for
the core cohort and 1.55 months for the extension
cohort. Interestingly though, 5 patients went on to receive
maraviroc in combination with chemotherapy, presumably
chemotherapy they had previously been resistant to, and 3
out of these 5 patients had objective partial responses.
Improved treatment strategies for patients with CRC
are clearly needed and immunotherapeutic approaches
are highly promising. Unfortunately, MSS CRCs have
been largely resistant to immunotherapeutic approaches,
such as single agent checkpoint blockade. The tumor
microenvironment has been implicated in this resistance
in multiple studies including this study by Halama and
colleagues. This study, however, has multiple caveats.
This is a very small study that unfortunately did not
meet its primary endpoint of demonstrating efficacy with
CCR5 inhibition. The most intriguing story in this
manuscript relates to the potential of CCR5 inhibition to
result in re-sensitization to chemotherapy. The exact
mechanism by which this might occur is unknown
though presumably occurs as a result of mitigation of
the tumor promoting effects of CCR5 signaling from the
microenvironment surrounding the cancer. This could
include alterations in signaling through chemokines,
cytokines and growth factors. The potential of CCR5 to
sensitize CRCs to chemotherapy would be further
supported had the authors confirmed that the patients
in the expanded cohort had previously progressed on
the chemotherapy used. It is also important to know
how long it had been since the patients were exposed to
these regimens. Tumors that progressed on a regimen
less than 6 months ago would not be expected to
respond, though if it had been longer than that a low yet
significant number of those cancers can respond to
retreatment.
Conclusion
Interesting activity has been demonstrated with CCR5
inhbiition in CRC. These results deserve further evalu-
ation in larger, better controlled, and more homoge-
neous subsets of patients with metastatic treatment
refractory colorectal cancer.
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